StockData

Assembly Biosciences vs Wave Life Sciences

ASMB and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASMB and WVE compare

Wave Life Sciences is the larger company, worth 1.2 times as much as Assembly Biosciences ($560M against $458M).

Assembly Biosciences keeps more of each dollar of sales as profit, with a net margin of −0.06% compared with −297% at Wave Life Sciences.

Assembly Biosciences scores higher on the StockData Score (12 against 10 for Wave Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASMBWVE
Size and price
Market cap$458M$560M
Share price$22.50$2.84
Change, 1 year−38.7%−59.9%
Change, 5 years−20.2%−28.8%
Beta (5Y)0.931.86
Employees73317
StockData Score
Total score12 (better)10
Valuation score23 (better)
Growth score11
Performance score3 (better)1
Health score6 (better)5
Dividend score00
Valuation
P/S6.1× (better)7.9×
P/B1.5×1.4× (better)
FCF yield−8.4% (better)−37.2%
Fair value$24.69$5.23
Margin of safety8.9%45.7% (better)
Growth
Revenue growth (TTM)125%–
Revenue growth, 5Y average−1.8%16.3% (better)
Profitability
Operating margin−11.8% (better)−321%
Net margin−0.06% (better)−297%
FCF margin−51.5% (better)−294%
Return on equity−0.03% (better)−80.0%
Financial health
Debt / equity0.000.00
Current ratio13.99 (better)8.38
Altman Z-score8.58 (better)−1.30
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions92.1%92.6%
Held by insiders29.3%23.1%
Insider net buying, 12 months−$252K$66.5M (better)
Superinvestors holding–1
Short interest, % of float21.1%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.